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1. Introduction 
The hypothesis that tumor growth may be sustained by a rare subpopulation of cells, 
termed cancer stem cells, is currently demonstrated in different types of cancer (Al-Hajj et 
al., 2004; Jordan et al., 2006; Reya et al., 2001). Brain tumor stem cells were isolated from 
primary brain tumors, such as malignant glioma (Galli et al., 2004; Hide et al., 2008). Glioma 
stem cells share some characteristics with normal neural stem cells, including the expression 
of neural stem cell markers, such as CD133 and Nestin (Hadjipanayis and Van Meir, 2009; 
Singh et al., 2004). Brain tumor stem cells possess the capacity for self-renewal and 
multipotency (ability to differentiate into neurons, astrocytes, and oligodendrocytes) and the 
proliferative ability for generation of many progeny. Furthermore, they are able to initiate 
new tumors in vivo when transplanted into immunocompromised mice even at low cell 
numbers (Galli et al., 2004). 
Glioma stem cells play an important role in tumor invasion and therapy resistance (Bao et 
al., 2006a; Calabrese et al., 2007; Dean et al., 2005; Hirschmann-Jax et al., 2004). Complete 
surgical resection is almost impossible because of the deep invasion to the normal brain 
parenchyma. Glioma stem cells have the ability to divide slowly and infinitely, which leads 
to the resistance to chemotherapy and radiotherapy. These stem cell-like properties allow 
glioma stem cells to survive selectively and initiate recurrence (Hide et al., 2008). 
Therapeutic strategy that target glioma stem cells may improve the prognosis of malignant 
glioma. Recent evidence has revealed that glioma stem cells are located in the highly 
vascular region, and glioma stem cells’ properties are tightly regulated by the 
microenvironment, so called vascular niche, similar to normal neural stem cells (Gilbertson 
and Rich, 2007; Yang and Wechsler-Reya, 2007). 
The development of new therapeutic strategies that target the glioma stem cells and 
vascular niche may result in more effective treatment of malignant glioma. In this article, we 
review the recent evidence on the biology of glioma stem cells associated with vascular 
endothelial growth factor (VEGF)- vascular endothelial growth factor receptor (VEGFR) 
signalling pathways for anti-angiogenic therapy. 
2. Brain stem cells and vascular niche 
Recent studies reveal a close relationship between the stem cells and the vascular niche. In 
the adult brain, neural stem cells were demonstrated to be concentrated around blood 
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vessels where they had access to signalling molecules, nutrition, and nascent vasculature for 
migration (Shen et al., 2004). Similarly, glioma stem cells were shown to be located around 
vascular niches (Calabrese et al., 2007). Vascular niche supplies oxygen and nutrition, and at 
the same time regulates the glioma stem cells’ characteristics, such as self-renewal and 
differentiation. In addition, glioma stem cells not only receive the signals from the 
surrounding niche but also modulate the signals through the secretion of VEGF (Bao et al., 
2006b; Folkins et al., 2009; Oka et al., 2007). Glioma stem cells and vascular niche represent 
integral factors for invasion and expansion. Therefore, comprehension of the interactive 
structural units may lead to development of therapeutic innovations. 
2.1 Neural stem cells   
Reynolds and Weiss were the first to isolate neural stem cells from the adult striatum that 
could proliferate and generate multipotent cells in vitro, termed neurospheres (Reynolds et 
al., 1992; Reynolds and Weiss, 1992). Neurosphere culture relies on a serum-free, selective 
growth factor (epidermal growth factor and fibroblast growth factor 2) system. Neural stem 
cells are responsive to the growth factor, and they can be passaged and expanded 
indefinitely with little change in characteristics. Removal of growth factors induces the 
differentiation of the progeny of neural stem cells into neurons, astrocytes, and 
oligodendrocytes. Neural stem cells have been isolated also from the subventricular zone 
lining of the lateral ventricles, dentate gyrus within the hippocampus, and subcortical white 
matter (Ayuso-Sacido et al., 2008; Eriksson et al., 1998; Nunes et al., 2003; Sanai et al., 2004). 
The subventricular zone is the largest of the germinal regions in humans. It is located 
between the ependymal layer of the lateral ventricles and parenchyma of the striatum. This 
zone is also thought to be the likely source of glioma stem cells (Sanai et al., 2005).  
2.2 Glioma stem cells    
Glioma stem cells are thought to originate from transformed neural stem cells and 
progenitor cell populations (Hadjipanayis and Van Meir, 2009). Clonogenic, neurosphere-
forming precursor cells were isolated from glioblastoma specimens by applying the same 
conditions used for the isolation of human neural stem cells. However, only 0.01%-1.0% of 
cells even in this selected population from malignant glioma can reinitiate tumors in 
immunodeficient mice (Hide et al., 2008). There are two major techniques for enrichment of 
glioma stem cells.  
One technique is cell sorting using a specific cell-surface antigen or a combination of the cell 
surface antigens. Purification of CD133-positive cells from human gliomas by flow 
cytometry can allow the isolation of glioma stem cells. CD133 was first reported as a marker 
for hematopoietic stem/progenitor cells (Yin et al., 1997). This cell-surface antigen was later 
reported as a marker for neural stem/progenitor cells (Uchida et al., 2000). Singh et al. 
demonstrated that as few as 100 CD133-positive glioma cells could initiate tumors in vivo 
when transplanted into immunocompromised mice; whereas, the injection of 5×104 to 1×105 
CD133-negative cells is not capable of tumor initiation (Singh et al., 2004). Recently, several 
reports have suggested that there is no difference in the ability of CD133-positive and 
CD133-negative cells to form orthotopic tumors (Zheng et al., 2007). CD133-negative cells 
isolated from glioblastoma were reported to form orthotopic tumors similar to CD133-
positive subpopulation (Chen et al., 2010; Wang et al., 2008). This may reflect the presence of 
other types of glioma stem cells. Further researches are needed to identify more specific cell-
surface antigen. 
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The other technique is side population technique using the ability to efflux Hoechst 33342 
dye (Hirschmann-Jax et al., 2004). The side population technique is a method to identify 
cancer stem cells in various cancers, including the brain (Hide et al., 2008). Cancer stem cells 
are thought to maintain their drug efflux ability, which makes it possible to separate cancer 
stem cells in unstained cell fractions. These cells appear on the lower left side of dot graphs 
analyzed by a cell sorter; hence, they are called side population cells.  
The current lack of a single marker to identify all cancer stem cells in malignant glioma may 
suggest the molecular heterogeneity among these cells.   
2.3 Glioma vascular niche 
Excessive and grossly disorganized blood vessel formation is a hallmark of glioblastoma. 
This aberrant vascularity has been presumed to be important for satisfying the demand for 
nutrition of the rapid tumor growth. Normal neural stem cells within the subventricular 
zone and hippocampus are concentrated in regions of the brain that are rich in blood 
vessels, called the vascular niche (Palmer et al., 2000). This organization places the stem cells 
in a close relationship with endothelial and other vascular cells, which facilitate 
communication among these cell types. The vascular niche protects neural stem cells from 
apoptotic stimuli to maintain a good balance between self-renewal and differentiation. 
Similarly, glioma stem cells were intimately associated with the vascular niche in the tumor. 
CD133-positive/nestin-positive glioma stem cells were frequently discovered close to 
capillaries within glioblastoma (Calabrese et al., 2007). Endothelial cells have been shown to 
be one of the most important components in the vascular niche. Endothelial cells secrete 
paracrine factors that promote normal stem cell survival and self-renewal (Shen et al., 2004). 
In the same manner, CD133-positive glioma stem cells when transplanted with endothelial 
cells grew more rapidly than when transplanted alone (Calabrese et al., 2007). In addition, 
tumors established in the presence of endothelial cells contained up to 25 times more 
CD133-positive cancer stem cells. Thus, endothelial cells are demonstrated to develop the 
self-renewal capacity of CD133-positive glioma stem cells. 
Recent evidence has suggested that a functional relationship between the glioma stem cells 
and vascular niche may be bidirectional; such that, the glioma stem cells may maintain the 
vascular niche just as the vascular niche helps in the proliferation and self-renewal of glioma 
stem cells. Bao et al. showed that high-level production of VEGF by CD133-positive glioma 
stem cells could develop their tumor-initiating capacity (Bao et al., 2006b). The authors 
demonstrated that freshly resected CD133-positive glioma cells increased endothelial 
migration and tube formation by producing VEGF, leading to vascular-rich and 
hemorrhagic tumors in the brains of immunocompromised mice, but not for the CD133-
negative glioma cells.  
3. Angiogenesis and VEGF family 
Angiogenesis is a tightly regulated process in which the development of new blood vessels 
arises from a pre-existing vascular network. It is regulated by endogenous activators and 
inhibitors during development and by normal physiological processes, such as wound 
healing. However, angiogenesis is also involved in tumor growth, progression, and 
metastasis (Hoeben et al., 2004). As a key step in tumor development, the angiogenic switch 
occurs when endogenous activators of angiogenesis exceed endogenous inhibitors 
(Hanahan and Folkman, 1996). This phenomenon results in increasing blood vessel 
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formation and supplying tumors with oxygen and nutrition for growth. However, tumor 
vasculature is disorganized and poorly structured; but is nonetheless essential for 
continuous tumor growth. Folkman et al. firstly proposed that tumor growth was restricted 
in size because there was limitation in the diffusion of oxygen without the blood supply, 
and so tumor angiogenesis could be a potential therapeutic target (Folkman, 1971; Folkman, 
1972; Folkman et al., 1971). Of the angiogenic factors, VEGF has been demonstrated to play a 
crucial role in angiogenesis and progression of malignant glioma (Plate et al., 1992).  
3.1 New blood vessel formation in glioma  
Formation of new blood vessels is classified into three models: angiogenesis, vasculogenesis, 
and arteriogenesis (Tate and Aghi, 2009). Angiogenesis is the formation of new blood 
vessels by rerouting or remodeling pre-existing vessels, and it is thought to be the primary 
method of vessel formation in gliomas. Vasculogenesis is classically considered an 
embryonic process, but recently it has been identified in adults, too. Vasculogenesis in 
tumors has been demonstrated to be the formation of blood vessels from circulating 
marrow-derived endothelial progenitor cells that are recruited to the tumor. Finally, 
arteriogenesis is a process in which arteriolar networks hypertrophy in order to sustain 
increased oxygen demands. A current model of tumor vessel formation suggests that this 
process involves recruitment of sprouting vessels from existing blood vessels and 
incorporation of endothelial progenitors into the growing vascular bed. Thus, only 
angiogenesis and vasculogenesis were thought to play important roles in tumor biology. 
The necrotic and hypoxic nature of glioblastoma is thought to cause angiogenesis and 
vasculogenesis through the induction of angiogenic factors including VEGF (Onishi et al., 
2011). 
3.2.1 VEGF family 
The vascular endothelial growth factor (VEGF) family consists of five members: VEGF-A 
(thereafter called VEGF), VEGF-B, VEGF-C, VEGF-D, and placental growth factor (PlGF) 
(Kowanetz and Ferrara, 2006). In addition, multiple isoforms of VEGF, VEGF-B, and PIGF 
are generated through alternative splicing of pre-mRNA (Sullivan and Brekken, 2010). 
VEGF family ligands show different affinities for the three VEGF tyrosine kinase receptors: 
VEGF receptor (VEGFR)-1, VEGFR-2, and VEGFR-3. Moreover, several co-receptors, such as 
neuropilins (Nrp)-1 and Nrp-2, also regulate VEGF family interaction with VEGFRs.  
3.2.2 VEGF(-A)  
The VEGF gene contains eight exons and seven introns. VEGF binds to VEGFR-1, VEGFR-2, 
Nrp-1, and Nrp-2. VEGF induces vascular permeability and also functions as an endothelial 
cell mitogen and survival factor, and an inducer of endothelial cell and monocyte migration 
(Kowanetz and Ferrara, 2006). Knock out studies in mice showed that homozygous or 
heterozygous deletion of the VEGF gene was embryonically lethal, resulting in defects in 
vasculogenesis and cardiovascular abnormalities. These studies have demonstrated that 
VEGF is essential for development. VEGF is important to postnatal angiogenic processes 
such as wound healing, ovulation, and pregnancy. VEGF is also involved in tumor 
angiogenesis, arthritis, macular degeneration, and diabetic retinopathy. VEGF is considered 
to be a strong angiogenic effector under most physiological and pathological conditions 
(Hicklin and Ellis, 2005; Sullivan and Brekken, 2010). 
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3.2.3 VEGF-B  
VEGF-B binds to both VEGFR-1 and Nrp1. The function of VEGF-B is still controversial. 
VEGF-B null mice were viable and largely healthy, except for some abnormalities in cardiac 
conduction (Sullivan and Brekken, 2010). VEGF-B plays some roles in heart function in 
adults, but not in developmental angiogenesis or cardiovascular development (Sullivan and 
Brekken, 2010). Therefore, VEGF-B has been thought to have a negligible role as an 
angiogenic factor even under pathological conditions. However, recent studies revealed that 
VEGF-B was a potent survival factor for blood vessels, and the inhibition of VEGF-B lead to 
pathological angiogenesis by abolishing blood vessel survival in animal models (Hicklin 
and Ellis, 2005). 
3.2.4 VEGF-C   
VEGF-C binds to VEGFR-2 and VEGFR-3. It is involved in developmental lymphangiogenesis 
and in the maintenance of adult lymphatic vasculature (Sullivan and Brekken, 2010).  
VEGF-C null mice were embryonic lethal and heterozygous VEGF-C loss was characterized 
by lymphedema because of defective development of the lymphatic vasculature. VEGF-C is 
not necessary for blood vessel development because vessels appear normal in VEGF-C null 
animals (Sullivan and Brekken, 2010). Although VEGF-C is not expressed in a normal brain, 
recent reports that show the high expression of VEGF-C in malignant glioma suggest the 
ligands’ role in glioma angiogenesis (Grau et al., 2007; Jenny et al., 2006; Witmer et al., 2001). 
3.2.5 VEGF-D   
VEGF-D binds to both VEGFR-2 and VEGFR-3. VEGF-D is also involved in developmental 
lymphangiogenesis and adult lymphatic vasculature (Sullivan and Brekken, 2010). VEGF-D 
null mice were viable and had a normal lymphatic vasculature during development and in 
adults, which suggests that VEGF-C and other growth factors may substitute for VEGF-D 
function. VEGF-C and VEGF-D bind to VEGFR-2 and they might also play a role in 
angiogenesis as well, especially during pathological states such as tumor growth. However, 
the role of these ligands in tumor angiogenesis is unclear. Similar to VEGF-C, VEGF-D is 
shown to be expressed highly in malignant glioma but not in the normal brain, which 
suggests the ligands’ contribution to glioma angiogenesis (Grau et al., 2007; Witmer et al., 
2001). 
3.2.6 VEGF-E   
VEGF-E is not a mammalian VEGF homolog, but rather a viral protein encoded by the 
parapoxvirus Orf virus (Shibuya, 2003). VEGF-E binds to only VEGFR-2. It is also involved 
in angiogenesis like VEGF-A but its role still remains unclear.   
3.2.7 Placental growth factor   
Placental growth factor (PlGF) binds to only VEGFR-1 and is also involved in angiogenesis 
(Hicklin and Ellis, 2005). PlGF is also suggested to play the role in recruitment of monocyte 
and vascular progenitor cells from bone marrow to tumors. This ligand is primarily 
expressed in the placenta, and also in other organs such as the heart, retina, and muscle 
(Sullivan and Brekken, 2010). Although PlGF null mice were viable and displayed no defect 
in embryonic angiogenesis or developmental abnormalities, the loss of PlGF impaired 
angiogenesis, plasma extravasation, and collateral growth during ischemic conditions, 
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inflammation, wound healing, and tumor growth (Hicklin and Ellis, 2005). Lastly, PlGF may 
play important roles on pathologic states in adult. 
3.2.8 VEGF family expressions in glioma cells 
The over-expression of VEGF in glioma was demonstrated (Plate et al., 1992), and recent 
studies also revealed the over-expression of VEGF in glioma stem cells by evaluating 
expression levels of VEGF in conditioned media from matched CD133+ and CD133- glioma 
cultures (Bao et al., 2006b). High expression of VEGF-B mRNA was shown in low and high 
grade gliomas (Gollmer et al., 2000). Grau SJ et al. analyzed expressions of VEGF-C, VEGF-D, 
and VEGFR-3 in glioblastomas, and showed strong protein expression of VEGFR3 on tumor 
endothelium, while VEGF-C and VEGF-D were expressed on numerous cells in areas of 
high vascularization (Grau et al., 2007). Although VEGF-C, VEGF-D, and VEGFR-3 are not 
expressed in normal brain tissue, expressions of VEGFR3, VEGF-C and VEGF-D were found 
on the protein and RNA levels. Nomura et al. investigated the relationship between PlGF 
and primary brain tumor angiogenesis. PlGF mRNA was expressed in all the hypervascular 
primary brain tumors (Nomura et al., 1998). In addition, they conducted hypoxic 
experiments with cultured U-251MG human glioma cells to determine the mechanism of 
PlGF gene regulation. As the atmospheric oxygen concentration was decreased, the PlGF 
mRNA level in the U-251MG cells was markedly increased. These results suggested that 
PlGF may contribute to the pathogenesis of brain tumor angiogenesis.  
Until now, it has been demonstrated that only VEGF is expressed highly in glioma stem 
cells.  
3.3.1 VEGF receptors   
There are three receptor tyrosine kinases that mediate the angiogenic functions of VEGF 
family members (Kowanetz and Ferrara, 2006). They are structurally very similar. The VEGF 
receptors contain a seven immunoglobulin-like domain extracellular region, a single 
transmembrane domain segment, a juxtamembrane segment, a split intracellular protein-
tyrosine kinase domain, and a carboxyterminal tail. Unlike other VEGFR genes, alternative 
splicing of VEGFR-1 produces a soluble form of the receptor (sVEGFR-1) that contains only 
extracellular domain (Sullivan and Brekken, 2010). This receptor does not possess the 
activity of tyrosine kinase in intracellular signaling, and inhibits the function of VEGF. 
VEGFR-1 and VEGFR-2 were originally identified on endothelial cells, and VEGFR-3 was 
identified on lymphatic endothelial cells (Kowanetz and Ferrara, 2006). 
3.3.2 VEGFR-1   
VEGFR-1 is a receptor for VEGF, VEGF-B, and PlGF. It binds VEGF with at least 10-fold 
higher affinity than VEGFR-2, but the kinase activity is weaker than that of VEGFR-2 
(Sullivan and Brekken, 2010). Although VEGFR-1 null mice were embryonic lethal, the mice 
that did not express the tyrosine kinase domain of VEGFR-1 but retained the ligand-binding 
extracellular domains and transmembrane segment (VEGFR1-TK-/-) were viable. Thus, 
VEGFR-1 was initially considered to be a negative regulator of VEGF activity by acting as a 
decoy receptor for VEGF. VEGFR-1 was also expressed by monocytes, macrophages, and 
other bone marrow-derived progenitor cells (myeloid cells) with cell-surface marker of 
CD11b (Kaplan et al., 2005). VEGFR-1 was thought to mediate the migration of bone 
marrow-derived cells into cancerous tissues and recruitment of endothelial progenitor cells 
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as another function resulted in tumor growth and angiogenesis (Sullivan and Brekken, 
2010). VEGFR-1 null mice were embryonic lethal because of excessive hemangioblast 
proliferation and poor organization of vascular structures, which seemed to be due to the 
inhibition of the function as a negative regulator for VEGF signaling and the inhibition of 
angiogenesis via recruitment of endothelial progenitor cells. In addition, VEGFR-1 was also 
shown to be expressed by the subsets of liquid and solid tumor stem cells, which resulted in 
tumor cell survival and growth (Kowanetz and Ferrara, 2006). Although VEGFR-1 must be 
critical for physiologic and developmental angiogenesis, the precise function of VEGFR-1 
remains unclear. Recent studies have shown that during pathologic conditions such as 
tumorigenesis, VEGFR-1 is a potent, positive regulator of angiogenesis (Hicklin and Ellis, 
2005). Hence, current evidence has suggested that the function of VEGFR-1 differs with each 
stage of development, various states of physiologic and pathologic conditions, and cell types 
in which it is expressed. 
3.3.3 VEGFR-2   
VEGFR-2 is the major mediator of VEGF-induced angiogenic signalling. The functions of 
VEGFR-2 include endothelial cell survival, migration, proliferation, and vascular 
permeability. This receptor has the most important role in vessel formation during both 
physiologic and pathologic conditions (Hicklin and Ellis, 2005). Recent studies have shown 
that VEGFR-2 is also expressed in subsets of liquid and solid tumor cells in addition to 
endothelial cells, which imply the additional role of VEGF in cancer through stimulation of 
VEGFRs on tumors cells (Hicklin and Ellis, 2005; Kowanetz and Ferrara, 2006). VEGFR-2 is a 
receptor for VEGF, VEGF-B, VEGF-C, VEGF-D, and VEGF-E. VEGFR-2 has a lower affinity 
for VEGF than VEGFR-1, but it has a stronger kinase activity. VEGFR-2 null mice were 
embryonic lethal (Sullivan and Brekken, 2010). These animals had severe defects in 
endothelial and hematopoietic cell development with no organized blood vessel found at 
any point within the developing embryo or the yolk sac.  
3.3.4 VEGFR-3   
VEGFR-3 binds both VEGF-C and VEGF-D and is a key regulator of normal and tumor 
lymphangiogenesis (Hicklin and Ellis, 2005; Kowanetz and Ferrara, 2006; Sullivan and 
Brekken, 2010). During development and in adulthood, its expression is limited to 
lymphatic endothelial cells. VEGFR-3 is also expressed in the embryonic vasculature. 
VEGFR-3 null mice were embryonic lethal and displayed cardiovascular failure as a result of 
the abnormal structure and organization of large vessels. VEGFR-3 is not expressed in the 
brain, but recent studies have shown that VEGFR-3 is expressed highly with VEGF-C and 
VEGF-D in malignant glioma endothelium, which may suggest that VEGFR-3 and these 
ligands contribute to glioma angiogenesis (Grau et al., 2007; Jenny et al., 2006). 
3.3.5 VEGFRs expressions in glioma cells 
The expression of VEGFRs on liquid and solid tumor cells has been reported already (Dias et 
al., 2001; Dias et al., 2000; Ferrer et al., 1999). VEGF may also have another role in cancer 
through the stimulation of VEGFRs on tumor cells. Although the significance of this 
expression is still under investigation, it has been hypothesized that VEGF ligands promote 
tumor growth not only in a paracrine manner, but also in an autocrine manner. Rafii et al. 
showed that functional VEGF/VEGFR-2 autocrine loop was present in subsets of human 
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leukemias and supported in vivo leukemic cell survival and migration (Dias et al., 2000). Fan 
F et al. demonstrated that VEGFR-1 activation by VEGF or VEGF-B led to activation of the 
MAPK pathway in tumor cells and phenotypic changes including an increase in cell 
migration and invasion (Fan et al., 2005).  
Knizetova et al. demonstrated that the expression of VEGFR-1 and VEGFR-2 genes in 
glioma cells was shown by PCR (Knizetova et al., 2008). They reported autocrine regulation 
of glioblastoma cell proliferation. Lucio-Eterovic et al. showed the mRNA and protein levels 
of VEGFRs in glioma stem cell line, suggesting that autocrine VEGF signalling blockade 
played an important role in glioma invasion (Lucio-Eterovic et al., 2009). 
The expression of VEGFR-3 in glioma cells, including glioma stem cells, is still unreported. 
3.4 VEGFR signaling molecular pathways 
Receptor tyrosine kinases (RTKs) are transmembrane proteins that mediate the transmission 
of extracellular signals to the intracellular environment. RTKs are activated through the 
binding of a growth factor ligand to the extracellular domain, leading to receptor 
dimerization and subsequent autophosphorylation of the receptor complex by the 
intracellular kinase domain, using ATP. The phosphorylated receptor then interacts with a 
variety of cytoplasmic signaling molecules, leading to signal transduction.  
In VEGFR-2 intracellular signaling pathways, main signalling cascades include the 
phospholipase C┛(PLC┛)-protein kinase C-Raf kinase-mitogen-activated protein kinase 
kinase (MEK)-MAPK pathway and Phosphatidylinositol-3-Kinase(PI-3K)/AKT pathway. 
The PLC-┛ pathway regulates cell proliferation and cell migration. The PI-3K pathway 
regulates cell migration and cell survival via anti-apoptosis effect. The PI-3K pathway also 
regulates vascular permeability via heat shock protein 90 (Hsp90) and endothelial nitric 
oxide synthase (eNOS), but the signal is still not well understood (Kowanetz and Ferrara, 
2006). Unlike other RTKs, such as epidermal growth factor receptor (EGFR) and platelet-
derived growth factor receptor (PDGFR), the Ras pathway is not involved so strongly in the 
VEGFR-2 signalling pathway. 
In VEGFR-1 and VEGFR-3 intracellular signaling pathways, a limited number of signalling 
effectors have been shown to act downstream of these receptors. Further investigation for 
these receptors in cancer cells is required.    
4. VEGF/VEGFR-related molecular biology of malignant glioma  
4.1 Glioma invasion and angiogenesis 
Marked proliferation, angiogenesis, and invasion are hallmarks of malignant gliomas. 
Magnetic resonance imaging (MRI) showed two characteristic regions of malignant glioma; 
the central region with gadolinium-enhanced mass and the marginal region with high-
intensity signals on T2-weighted images. Histopathological analysis of malignant glioma 
invasion showed that the clusters of glioma cells and necrotic tissue were seen in the central 
region with gadolinium contrast enhancement. In the marginal region with high-intensity 
signals on T2-weighted images, diffuse infiltrating glioma cells were seen around and inside 
the normal brain parenchyma. Vascular proliferation was seen in both regions. (Onishi et al., 
2011) Glioma cells, including glioma stem cells, are beside newly developed vessels and had 
a close interaction with vascular niche especially in the paracrine manner. High-level 
expression of VEGF family and VEGFRs has been shown in glioma vasculature and glioma 
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cells, including glioma stem cells (Hicklin and Ellis, 2005). Glioma stem cells expressed 
higher levels of VEGF than the matched non-stem glioma cells and displayed greater 
angiogenic potential in vitro and in vivo (Bao et al., 2006b). Furthermore, recent studies have 
demonstrated that the relationship between glioma stem cells and vasculature is complex 
and bi-directional. Therefore, anti-angiogenic therapy has the potential to function as an 
anti-glioma stem cell therapy (Folkins et al., 2009; Oka et al., 2007). Calabrese et al. have 
demonstrated that the treatment of mice with VEGF inhibitor after glioblastoma 
implantation resulted in a large reduction in the number of glioma stem cells and blood 
vessels of the tumors. In contrast, VEGF inhibitor had minimal effect on the proliferation or 
survival of most cells in the tumors, suggesting that the glioma stem cells were targeted 
(Calabrese et al., 2007).    
Necrotic tissue in the central region of malignant glioma was surrounded by 
pseudopalisading cells. Recently, Rong et al. demonstrated that pseudopalisading cells were 
present in severely hypoxic regions, over-expressed hypoxia-inducible factor, and secreted 
VEGF (Rong et al., 2006). Pseudopalisading cells were cell populations composed of a series 
of actively migrating glioma cells, moving away from a central hypoxic region. Hypoxia 
activated the VEGF promoter and transcription in glioma cells, which could have led to the 
cell activation of a migrating phenotype toward the viable vessels (Brat et al., 2004). Both in 
vitro and in vivo models have demonstrated that tumor hypoxia results in increased glioma 
cell migration (Elstner et al., 2007). 
The autocrine function of VEGF in cancer invasion was first shown in invasive breast cancer 
cell lines (Bachelder et al., 2002; Price et al., 2001). In malignant glioma, tumor hypoxia may 
also increase tumor invasion in a VEGF/VEGFR autocrine manner independent of 
angiogenesis. Autocrine stimulation of VEGFRs on glioma cells including glioma stem cells, 
has been shown to be important for cell survival, proliferation and invasion (Knizetova et al., 
2008). In addition, hypoxia can promote the expansion of glioma stem fraction and regulate 
the expression of stem cell markers (Heddleston et al., 2009; McCord et al., 2009; Soeda et al., 
2009). Hypoxic condition induced VEGF expression in both glioma stem cells and non-stem 
glioma cells, but the VEGF levels were consistently higher in glioma stem cells (Li et al., 
2009). Under normoxic condition, glioma stem cells also expressed a higher level of VEGF 
than non-glioma stem cells.  
In addition, other histopathological findings as glioma invasion models were reported; such 
that glioma cell infiltrations into normal brain parenchyma independent of vasculature 
(Onishi et al., 2011). Cancer stem cells have been shown to promote metastasis (Hermann et 
al., 2007; Li et al., 2007). Although malignant gliomas rarely metastasize beyond the central 
nervous system, MRI sometimes shows glioma cells infiltration to contralateral hemisphere. 
This infiltrative feature away from tumor vascular niche may be equivalent to metastasis. 
Recent evidences in lung cancer have demonstrated that immature myeloid cells can be 
recruited to the metastatic sites and immature myeloid cells prepare to make the pre-
metastatic state for cancer cells (Kaplan et al., 2005). Immature myeloid cells express VEGFR-
1, and a neutralization antibody for VEGFR-1 has been shown to significantly suppress the 
metastasis in lung cancer (Hiratsuka et al., 2002). This evidence may suggest that bone 
marrow-derived cells, such as immature myeloid cells, are other components of the niche, 
and these cells are associated with glioma cells invasion via VEGF signalling pathways. 
Folkins et al. investigated that bone marrow-derived cells recruitments in mice with glioma 
stem cell-rich xenograft tumor (Folkins et al., 2009). Glioma stem cells were shown to 
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increase the mobilization of endothelial progenitors, but not myeloid cells. Further 
researches are required to show the possibility that the myeloid cells may be associated with 
glioma cells invasion.  
In summary, the VEGF paracrine signals between glioma cells and vascular niche enhance 
glioma cells invasion in the vascular-rich regions. In addition, the VEGF autocrine signals on 
glioma cells also enhance self-invasion in the hypoxic regions. As another component of the 
niche, myeloid cells may be involved in glioma cells invasion via VEGF signalling 
pathways. In particular, glioma stem cells have stronger signals of VEGF under various 
situations.  
4.2 Therapeutic resistance of glioma stem cells 
As well as regulating stem cell proliferation and survival, niche may also play a protective 
role of shielding stem cells from environmental insults (Moore and Lemischka, 2006). It was 
demonstrated that vascular niche could protect glioma stem cells from chemotherapy and 
radiotherapy (Huang et al., 2010). In fact, it was shown that the postoperative first-line 
chemotherapy for malignant glioma, temozolomide, was not so effective for glioma stem 
cells (Liu et al., 2006).  
Anti-angiogenic therapy is thought to have the potential to improve such therapy resistance. 
VEGF was one of the most characteristic permeability factors and it was demonstrated to 
contribute to BBB breakdown in gliomas directly (Tate and Aghi, 2009). Increased 
permeability of tumor blood vessels induced by VEGF resulted in elevated interstitial 
pressure and significant intracerebral edema. The elevated interstitial pressure decreases the 
transport of medication to tumor cells. In addition, chemotherapy and radiotherapy are less 
effective in the hypoxic area. Jain et al. proposed that the normalization of tumor 
vasculature by anti-angiogenic therapy could decrease brain edema, enhance drug delivery 
and increase radiation sensitivity (Jain, 2005). Vredenburgh et al. has reported that 
bevacizumab (VEGF inihibitor) in the combination with irinotecan (cytotoxic drug) was an 
effective treatment for recurrent malignant glioma (Vredenburgh et al., 2007). The 
normalization of tumor vasculature resulted in decresed interstitial pressure, less hypoxia, 
and increased delivery of irinotecan to tumor. The auther concluded that the efficacy seen 
with the combination of bevacizumab and irinotecan could be explained by the anti-tumoral 
stem cell effect of bevacizumab and by the anti-differentiated glioma tumor cell effect of 
irinotecan.  
Radiation therapy was demonstrated to induce VEGF expression in glioma cells (Hovinga et 
al., 2005). It was also demonstrated that VEGF blocked the killing of endothelial cell by 
radiation (Gorski et al., 1999). The radiation-enhanced VEGF secretion was associated with 
an increased angiogenic potential of the tumor, which thought to be a factor in 
radioresistance. Anti-VEGF therapy has the potential to prevent VEGF secretion after 
radiation and enhance radiation sensitivity. Recent studies have shown that glioma stem 
cells were more resistant to radiation than the matched non-stem glioma cells (Bao et al., 
2006a; Rich, 2007). In response to radiation-induced DNA damage, glioma stem cells 
preferentially activated several critical DNA damage checkpoint proteins. As a result of the 
preferential DNA damage checkpoint activation, glioma stem cells were more efficient in 
repairing the damaged DNA and more rapidly recover from the DNA damage than the 
matched non-stem tumor cells (Bao et al., 2006a). Thus, anti-angiogenic therapy enhances 
glioma cells’ and glioma stem cells’ sensitivity for cytotoxic chemotherapy and radiotherapy. 
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5. VEGF/VEGFR-related therapeutic target of malignant glioma 
An upregulation of VEGF family and the VEGF receptors has been shown in malignant 
gliomas and that can be a target for cancer therapy. In the anti-angiogenic therapy, drugs 
targeting anti-VEGF/VEGFR pathways have recently attaracted considerable attention. 
5.1 VEGF inhibitor 
Bevacizumab is a humanized monoclonal antibody that binds to VEGF-A, preventing it 
from binding to receptors and activating signaling cascades that lead to angiogenesis. The 
proof of the concept that targeting VEGF-A could inhibit the growth of tumors was 
demonstrated in a mouse model in 1993 (Kim et al., 1993). The first clinical trial was 
performed for the treatment of colorectal cancer. The first line chemotherapy (irinotecan, 
fluorouracil (5-FU), and leucovorin) with bevacizumab for colorectal cancer significantly 
increased the progression-free survival (PFS), as well as the median overall survival (OS), 
leading to FDA approval of bevacizumab as the first drug developed for anti-angiogenesis 
and anti-cancer use in humans (Hurwitz et al., 2004).  
Vredenburgh et al. performed a phase II trial to evaluate the efficacy of bevacizumab in 
combination with chemotherapy for malignant gliomas (Vredenburgh et al., 2007). 
Bevacizumab and irinotecan were administrated to 32 patients with recurrent high-grade 
glioma. The radiographic response was observed in 14 of 23 patients (61%). The median PFS 
for treated patients was 24 weeks, the 6-month PFS was 30%, and the overall median 
survival time was 42 weeks. This study suggested that bevacizumab in combination with 
irinotecan is an effective treatment for recurrent glioblastoma. Recently, Albert Lai et al. 
reported an open-label, prospective, multicenter single-arm phase II study that combined 
bevacizumab with radiation therapy (RT) and temozolomide (TMZ) for the treatment of 
newly diagnosed glioblastoma (Lai et al., 2011). In this study, 70 patients with newly 
diagnosed glioblastoma were enrolled between 2006 and 2008. Patients received standard 
RT starting within 3 to 6 weeks after surgery with concurrent administration of daily TMZ 
and biweekly bevacizumab. After completion of RT, patients resumed TMZ for 5 days every 
4 weeks and continued biweekly bevacizumab. OS and PFS were 19.6 and 13.6 months, 
respectively. Patients treated with bevacizumab and TMZ during and after RT showed an 
improvement of PFS but not OS compared to the control group.  
5.2 VEGF-Trap 
Aflibercept (VEGF-Trap, AVE0005) is a soluble fusion protein of the human extracellular 
domains of VEGFR-1 and VEGFR-2 and the Fc portion of human immunoglobulin (Ig) G. 
Aflibercept binds to both VEGF-A and PlGF with higher affinity than monoclonal antibodies 
and prevents theVEGF-A and PlGF ligands from binding and activating cell receptors. In 
vitro, aflibercept was shown to have an antiproliferative activity and completely blocked the 
VEGF-induced VEGFR-2 phosphorylation (Sullivan and Brekken, 2010). In xenograft 
models, tumor growth and tumor-associated angiogenesis were inhibited by aflibercept 
(Holash et al., 2002). Candelaria Gomez-Manzano et al. reported that treatment of animals 
bearing human gliomas with VEGF Trap resulted in a significant increase in the mean 
survival (Gomez-Manzano et al., 2008).  
5.3 VEGFR inhibitor 
In addition to VEGF inhibitors, small molecule inhibitors of VEGFR have been tested in 
recurrent malignant gliomas. They often target more than one type of receptor and affect 
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both endothelial cells and cancer cells because the receptors are expressed on both types of 
cells. Because the target kinase specificity between inhibitors can vary, different compounds 
have shown various levels of efficacy and activity between cancers (Sullivan and Brekken, 
2010; Kowanetz and Ferrara, 2006). Some of these agents include compounds that bind to 
the ATP binding site of the RTK, which block receptor activation, or with antibodies that 
bind to the growth factors or their receptors, which prevent the binding and subsequent 
activation of receptors. 
Cediranib (AZD2171) inhibits all known subtypes of VEGFR and has been evaluated in a 
phase 2 trial of patients with recurrent glioblastoma (Batchelor et al., 2010; Batchelor et al., 
2007). Results were comparable to those reported for bevacizumab, with a response rate of 
56% and a 6-month PFS rate of 26%. A striking steroid-sparing effect was observed. The 
drug was largely well tolerated, with hypertension, diarrhea, and fatigue as the most 
common adverse effects. Using dynamic contrast-enhanced MRI, it was demonstrated that 
cediranib therapy reduced blood vessel size and permeability. These are the first clinical 
data to support the hypothesis that antiangiogenic therapy may transiently "normalize" the 
dilated, abnormally permeable tumor vasculature.  Other VEGFR inhibitors in which clinical 
studies were conducted for malignant gliomas are listed in Table 1. 
 
Inhibitor Primary targets (other targets) Mechanism of action 
Bevacizumab VEGF-A Monoclonal antibody 
Aflibercept VEGF-A (VEGF-B, PlGF) Soluble decoy receptor 
Cediranib 
VEGFR-2 
(other VEGFR, PDGFR-┚, c-kit) Tyrosine kinase inhibitor 
Sorafenib 
VEGFR-2 
(other VEGFR, Raf, PDGFR-┚, c-kit, Ras, RET) Tyrosine kinase inhibitor 
Sunitinib 
VEGFR-2 
(other VEGFR, PDGFR-┚, Flt3, c-kit) Tyrosine kinase inhibitor 
Pazopanib 
VEGFR-2 
(other VEGFR, PDGFR-α,┚,c-kit) Tyrosine kinase inhibitor 
Vandetanib 
VEGFR-2 
(other VEGFR, EGFR) 
Tyrosine kinase inhibitor 
Vatalanib VEGFR-1,2 (PDGFR-┚, c-kit) Tyrosine kinase inhibitor 
Brivanib FGFR (VEGFR) Tyrosine kinase inhibitor 
CT-322 VEGFR-2 (other VEGFR) Adnectin 
XL-184 
VEGFR-2 
(c-Met, RET, c-Kit, Flt3, Tie-2) 
Tyrosine kinase inhibitor 
Table 1. VEGF/VEGFR related anti-angiogenic drugs in clinical development for high-grade 
glioma  
6. Summary and future outlook  
The existence of glioma stem cells prompts us to review the cancer biology. Gliomas appear 
to have a cellular hierarchy rather than a bulk of equally potent tumor cells. Within this 
hierarchy, glioma stem cells have an extraordinary capacity for tumor-initiation, and glioma 
stem cells are thought to be attractive targets for anti-glioma therapies. The development of 
novel treatments against glioma stem cells is expected as an urgent task. Glioma stem cells’ 
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properties are maintained with vascular niche, and vascular niche is maintained with VEGF 
secreted by glioma stem cells. Glioma stem cells and vascular niche make the bi-directional 
functional units. Of anti-angiogenic factors, VEGF family/VEGFRs are one of the most 
important therapeutic targets for these units. 
As the use of anti-angiogenic drugs such as bevacizumab becomes widespread, some 
problems surfaced. Firstly, the potential side effects that occur in the short-term or long-term 
use of angiogenesis inhibitors are becoming apparent (Norden et al., 2008). These side effects 
include gastrointestinal perforations, impaired wound healing, bleeding, hypertension, 
proteinuria, and thrombosis. These occurrences are unpredictable and further studies are 
needed to measure the risk for patients, understand the cause of complications, and find 
prophylactic measures to minimize risk. Secondly, it has been found that most tumors 
become to be resistant to anti-angiogenic drugs as a consequence of the long-term 
administration of anti-angiogenic drugs (Norden et al., 2008). Because multiple signaling 
pathways are involved in angiogenesis, blocking a single pathway may not be highly 
effective. The administration of single anti-angiogenic agent can lead tumors to acquire the 
resistance when the tumor cells develop other angiogenesis pathways. The combination 
drug therapies targeting multiple pathways may be able to overcome this problem. 
Therefore recently, clinical trials of combination drug therapies are performed such as other 
anti-angiogenic drugs, cytotoxic drugs or anti-invasion drugs (Van Meir et al., 2010). 
Thirdly, the further studies are needed to evaluate the administration protocol of anti-
angiogenic agents. For example, metronic dosing, which is administration of small doses of 
drugs in a rapid cycle, has the potential to improve in outcomes over standard dosing 
(Kesari et al., 2007). Kesari S et al. performed the phase 2 study of metronomic four drugs 
chemotherapy (etoposide, cyclophosphamide, thalidomide and celecoxib) for reccurent 
malignant gliomas (Kesari et al., 2008). Although this study did not show a significant 
improvement of OS in heavily pretreated patients who were generally not eligible for 
conventional protocols, there were some responders. It was suggested that further studies 
using metronomic chemotherapy combined with more potent anti-angiogenic agents in 
patients with less advanced disease may be warranted. 
Brain tumor stem cells have a bi-directional relationship with vascular niche. Anti-
angiogenic therapy is the strategy targeting for vascular niche, which may result in the 
strategy targetting for brain tumor stem cells. Accumulated evidence suggests that VEGF 
family/VEGFRs are strongly related with the biology of brain tumor stem cells. Thus VEGF 
family/VEGFRs signaling pathway is expected to be one of the most important targets of 
anti-angiogenic therapies for malignant gliomas.  
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